SIMBRINZA 10 mg/mL + 2 mg/mL eye drops, suspension
- Name:
SIMBRINZA 10 mg/mL + 2 mg/mL eye drops, suspension
- Company:
Novartis Ireland Limited
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may be renewed (B)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 12/10/20
(Click to Download)Click on this link to Download PDF directly
Novartis Ireland Limited
Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 12 October 2020 PIL
Reasons for updating
- Change to other sources of information section
Updated on 2 January 2020 SPC
Reasons for updating
- Change to section 5.1 - Pharmacodynamic properties
Legal category: Product subject to medical prescription which may be renewed (B)
Updated on 3 October 2019 SPC
Reasons for updating
- Change to section 4.6 - Pregnancy and lactation
Legal category: Product subject to medical prescription which may be renewed (B)
Updated on 29 August 2019 PIL
Reasons for updating
- Change to date of revision
Updated on 29 April 2019 PIL
Reasons for updating
- Change to date of revision
Updated on 11 April 2019 PIL
Reasons for updating
- Change to section 6 - date of revision
Updated on 8 April 2019 SPC
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 9 - Date of first authorisation/renewal of the authorisation
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Change in SmPC following renewal of the Marketing authorisation
Updated on 14 March 2019 PIL
Reasons for updating
- Change to date of revision
Updated on 29 May 2018 SPC
Reasons for updating
- Change to section 6.6 - Special precautions for disposal and other handling
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Adress change for the MAH from UK to Ireland
Updated on 30 May 2017 SPC
Reasons for updating
- New SPC for new product
Legal category: Product subject to medical prescription which may be renewed (B)
Updated on 30 May 2017 SPC
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - Marketing authorisation number(s)
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Updated on 19 May 2017 PIL
Reasons for updating
- New PIL for new product
Updated on 19 May 2017 PIL
Reasons for updating
- Change to section 6 - marketing authorisation holder
- Change to section 6 - marketing authorisation number
- Change to section 6 - date of revision
Updated on 3 August 2015 PIL
Reasons for updating
- Improved electronic presentation
Updated on 23 June 2015 SPC
Reasons for updating
- Change to section 5.1 - Pharmacodynamic properties
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Updated on 16 June 2015 PIL
Reasons for updating
- Change to MA holder contact details
Updated on 7 August 2014 SPC
Reasons for updating
- New SPC for new product
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Updated on 1 August 2014 PIL
Reasons for updating
- New PIL for new product